retatrutide type 2 diabetes trial results 2024 2025 💉 may be redefining obesity treatment. New data from TRIUMPH-1 showed: 🔥 ~28% average weight loss over 80 weeks 🔥 >30% weight loss in nearly half of participant #ObesityMedicine #Retatrutide #GLP1 #CardioMetabolic Michael Weintraub, MD on X:

The enhanced potency is due to the markedly decreased binding of Long-R3-IGF-I to IGF binding proteins which normally inhibit the biological actions of IGFs

Receptor Interactions and Molecular Targets Unlike many pharmacological agents with well-defined single receptor targets, BPC-157 appears to function through multiple cellular pathways and molecular interactions

Type 2 DM Pathophysiology: T2DM involves the interplay of insulin resistance (primarily at skeletal muscle, liver, and adipose tissue) and progressive beta-cell secretory failure

On top of this, some treatments are believed to boost blood circulation in the scalp and strengthen existing hair, potentially leading to improved hair density and texture

SURPASS-CVOT investigators

While pharmaceutical manufacturers conduct stability testing under various conditions, uncontrolled exposure during shippingparticularly during summer months or in hot climatesmay affect product quality